Sprint Bioscience ABOSTO:SPRINT -4.92%32 Days Payable is 216.24 as of Mar. 2026, which is 52% above its 10-year median of 141.91. GuruFocus rates OSTO:SPRINT with a GF Score™ of 32/100 and a GF Value™ of kr2.18 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 702 Biotechnology companies, Sprint Bioscience AB ranks better than 55.56% on this metric.
The historical rank and industry rank for Sprint Bioscience AB's Days Payable or its related term are showing as below:
OSTO:SPRINT'
s Days Payable Range Over the Past 10 Years
Min: 71.79 Med: 141.91 Max: 2702.22
Current: 141.71
During the past 13 years, Sprint Bioscience AB's highest Days Payable was 2702.22. The lowest was 71.79. And the median was 141.91.
OSTO:SPRINT's Days Payable is ranked better than 55.56% of 702
companies
in the Biotechnology industry
Industry Median: 113.56
vs OSTO:SPRINT: 141.71
Sprint Bioscience AB's Days Payable
increased
from Mar. 2025 (89.47) to Mar. 2026 (216.24).
It may suggest that Sprint Bioscience ABdelayed paying its suppliers.
Sprint Bioscience AB Days Payable Related Terms
Sprint Bioscience AB Days Payable Historical Data
* Premium members only.
The historical data trend for Sprint Bioscience AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SPRINT vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Sprint Bioscience AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sprint Bioscience AB Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Sprint Bioscience AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sprint Bioscience AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sprint Bioscience AB (OSTO:SPRINT) has a Days Payable of 216.24 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sprint Bioscience AB and its competitors. This is 52% above median its historical median of 141.91. Over the past decade, Sprint Bioscience AB's Days Payable has ranged from 71.79 to 2,702.22. According to the industry distribution chart, Sprint Bioscience AB ranks #312 out of 702 companies in the Biotechnology industry, placing it in the top 44.4%.
Is Sprint Bioscience AB's Days Payable too high?
Sprint Bioscience AB's current Days Payable of 216.24 is 52% above median its 10-year median of 141.91. Over the past 10 years, this metric has ranged from a low of 71.79 to a high of 2,702.22. The Biotechnology industry median Days Payable is 113.56. Sprint Bioscience AB's value of 216.24 is 90.4% above this industry median. Based on the distribution chart, Sprint Bioscience AB ranks #312 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sprint Bioscience AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sprint Bioscience AB ranks #312 out of 702 companies for Days Payable. This puts Sprint Bioscience AB in the upper half of its industry. The industry median Days Payable is 113.56. Sprint Bioscience AB's value of 216.24 is 90.4% above this benchmark. Historically, Sprint Bioscience AB's own Days Payable has ranged from 71.79 to 2,702.22 over the past decade. While the company's 10-year median is 141.91 vs. the industry median of 113.56, Sprint Bioscience AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sprint Bioscience AB's current Days Payable of 216.24 is 90.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sprint Bioscience AB and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sprint Bioscience AB's current Days Payable is 216.24, which is 52% above median its own 10-year median of 141.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Sprint Bioscience AB (OSTO:SPRINT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.18, compared to a current price of kr4.06 — trading 86.2% above its estimated fair value. The current Days Payable is 216.24, which is 52% above median its 10-year median of 141.91 and 90.4% above the Biotechnology industry median of 113.56. Sprint Bioscience AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current Days Payable is 216.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?
Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued.
The current stock price of kr4.06 is trading 86.2% above its estimated GF Value™ of kr2.18.
GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.
Key valuation signals for OSTO:SPRINT:
Days Payable: 216.24 (52% above median its 10-year median of 141.91)
GF Value™: kr2.18 vs. price of kr4.06 (86.2% above fair value)
Industry Position: 90.4% above the Biotechnology median (#312 of 702)
No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score
Get the complete analysis for OSTO:SPRINT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPRINT has been successfully added to your 
